Please assess the completion status of the following clinical trial:

Trial Title: Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed renal cell cancer with a component of clear cell subtype, with metastasis~* Evidence of measurable disease~* Must have failed one prior systemic first-line regimen for metastatic renal cell cancer~Exclusion Criteria:~* Prior treatment for metastatic renal cell cancer with more that one systemic first line therapy~* Major surgery less than 4 weeks or radiation less than 2 weeks of starting study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Axitinib (Type: EXPERIMENTAL): None
- Sorafenib (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).